logo
Share SHARE
FONT-SIZE Plus   Neg

GE Healthcare Reveals Phase 3 Results For Imaging Agent Flutemetamol

GE Healthcare, a unit of diversified conglomerate General Electric Co. (GE), Wednesday released results from four pooled brain biopsy studies and results from a brain autopsy study of the investigational PET amyloid imaging agent, flutemetamol.

The results revealed that both biopsy and autopsy study images had high sensitivity and specificity, and that strong concordance exists between flutemetamol PET images and Alzheimer's disease-associated beta amyloid brain pathology.

The data confirm the potential of flutemetamol as an imaging agent to detect beta amyloid plaque, a pathology associated with Alzheimer's disease in living patients.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Millennials rely more on social networking site Facebook Inc. (FB) for their political news than Baby Boomers, a survey released by Pew Research Center showed. Data storage firm NetApp Inc. (NTAP) Monday said Chief Executive Officer and Chairman Tom Georgens has stepped down. The company has appointed George Kurian, executive vice-president of product operations, as the new CEO. Georgens' resignation comes just couple of weeks after NetApp reported a fourth-quarter... Apparel maker PVH Corp. said Monday after the markets closed that its first quarter profit rose sharply from last year, when results were weighed down by debt modification and extinguishment costs. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
RELATED NEWS
Trade GE now with 
Follow RTT